SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as community members highlight its strong community, real-world applications, and growing holder count. The community emphasizes a 'we don't gamble, we work' ethos, with community-led initiatives and real-world products like Kendu Energy driving excitement. Discussions also focus on positive distribution metrics and anticipation for the next alt-season.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as investors anticipate a potential rate cut decision from the Federal Reserve, while some traders express concerns about overvaluation and a possible "sell the news" event. Community chatter revolves around the sustainability of the current rally, with discussions about market mechanics, potential pullbacks, and the impact of the Fed's actions, as well as signs that insiders are selling.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending due to the withdrawal of a planned share offering, sparking speculation of a potential merger or acquisition and a possible short squeeze, especially with a relatively low float. The community is actively discussing price targets and the potential for significant upward movement, fueled by the reduced risk of dilution. Some traders believe the stock may experience halts and a parabolic run, while others are focused on technical levels and potential breakout points.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending as community members discuss Elon Musk's recent $1 billion stock purchase and its potential impact, with some viewing it as a signal of confidence. Discussions range from short squeezes and potential price targets to debates about the company's fundamentals and future prospects. Some traders are also speculating about potential connections to AI and the acquisition of TikTok.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid retail interest possibly sparked by a congressional disclosure of stock purchases and speculation around future government contracts, drawing comparisons to Palantir ($PLTR). Bullish investors are actively analyzing chart patterns, anticipating a short squeeze, and expressing optimism about the company's AI-driven solutions within the growing AI for defense and security sector.

Slopana

Slopana is gaining attention as a Solana-based meme coin, with the community rallying behind its "digital slop" identity. Discussions highlight its availability on Phantom Wallet and the growing excitement around its potential within the Solana ecosystem. The community emphasizes its strong base and CTO leadership as driving factors.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia ($JMIA) is trending amid discussions about a potential breakout, driven by recent positive movement and a renewed focus on the company's improving financials. Community members are closely watching the stock's performance, with some suggesting a potential run to higher price targets. Investors are also discussing the broader context of Jumia as an e-commerce play in the African market, citing its unique position and growth potential.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending amid speculation around its involvement in a potential TikTok deal and its broader implications for the company's cloud business and AI initiatives. Community discussions revolve around potential price targets, the likelihood of a deal confirmation, and the impact on ORCL's market capitalization. Some traders are also weighing potential insider selling and the stock's technical outlook following its recent earnings-driven surge.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders debate the sustainability of the current market rally, particularly within the semiconductor sector, with some community members pointing to stretched valuations and anticipating a pullback. Discussions revolve around potential catalysts like upcoming economic data and earnings reports, while others express concern about the disconnect between market performance and underlying economic realities. Some traders believe the current environment is presenting a chance to profit from inverse ETFs.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as investors anticipate a potential Federal Reserve rate cut, while some community members express concern about a potential "sell the news" event if the cut occurs. Community sentiment is divided, with some seeing continued upward momentum and others predicting a pullback. Broader market themes include discussions around AI, tariffs, and potential impacts from political and economic events.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

​Retail interest for Phathom Pharmaceuticals soared on Thursday after the company reported first-quarter results, unveiled a sweeping cost-reduction plan and reaffirmed its target to achieve operational profitability by 2026.The company posted Q1 revenue of $28.5 million, slightly below the $29.02 million consensus.&nbsp;Its net loss widened to $94.3 million from $82.9 million a year earlier, driven largely by increased advertising and promotional spend for its lead drug, VOQUEZNA.“2025 will be an inflection point for Phathom,” said CEO Steve Basta.&nbsp;The company announced a 6% workforce reduction, multiple leadership changes, and significant cuts in external spending.&nbsp;Phathom expects the moves to reduce 2025 operating expenses by $60 million to $70 million and lower quarterly spend to under $55 million by the fourth quarter.Basta said the company’s actions are designed to support long-term growth without raising new equity or debt. He added that sales force strength remains a top priority, with commercial personnel now comprising around 75% of the total workforce.Voquezna prescriptions rose 8% sequentially in Q1 to 127,000, while cumulative prescriptions surpassed 390,000 as of April 18.&nbsp;Commercial access remained strong, with coverage extending to over 120 million lives, including more than 80% of commercially insured patients.Phathom also paused its planned Phase 2 trial for eosinophilic esophagitis and is awaiting an FDA decision on its citizen petition seeking full NCE exclusivity through 2032.Retail traders on Stocktwits remained optimistic despite the revenue miss, with sentiment marked as ‘bullish’ amid a 900% surge in 24-hour messaging volume.&nbsp;Several users said they were buying the dip, expressing continued confidence in the company’s long-term prospects.<stembedurl>https://stocktwits.com/DrDare/message/613236534</stembedurl>One user said the volume spike was notable but still lower than on days when major patent or executive updates had occurred.&nbsp;<stembedurl>https://stocktwits.com/Morrito23/message/613282417</stembedurl>They noted persistent concerns over cash burn, but said they welcomed management's move to finally address the issue publicly.Some traders described the first quarter as unusually difficult for pharmaceutical firms, citing formulary changes and deductible resets.&nbsp;Others saw the update as a turning point, with one saying the stock could become a buyout candidate if exclusivity concerns are resolved and revenue momentum continues.<stembedurl>https://stocktwits.com/Canvasback33/message/613238887</stembedurl>Shares of Phanthom have fallen 54.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Packaging and pills of different types of psychotropic medications are seen in this illustration photo taken in Warsaw, Poland on 22 April, 2025. (Photo by Jaap Arriens/NurPhoto via Getty Images)

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 

Equity

Phathom's Voquezna prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 


2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

2  ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAT News

PHAT Phathom Pharmaceuticals Inc